Related Experiment Videos
Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin
1Department of Radiation Oncology, Stanford University School of Medicine, California 94305-5468.
Cancer Research
|October 1, 1993
Summary
Tirapazamine combined with cisplatin significantly enhances tumor cell killing in mice. This combination therapy shows promise for cancer treatment without increasing kidney damage or systemic toxicity.
Area of Science:
- Oncology
- Pharmacology
- Radiotherapy
Background:
- Hypoxic tumor cells are resistant to chemotherapy and radiation.
- Tirapazamine selectively targets hypoxic cells.
- Tirapazamine is being investigated for combination with radiation therapy.
Purpose of the Study:
- To evaluate tirapazamine in combination with cisplatin (c-DDP) for enhanced tumor cell killing.
- To assess the toxicity profile of the tirapazamine-cisplatin combination.
Main Methods:
- In vivo and in vitro studies using mouse RIF-1 tumor model.
- Administered tirapazamine (SR 4233) and cisplatin (c-DDP) at various schedules.
- Assessed tumor cell killing, serum blood urea nitrogen levels, leukopenia, and systemic toxicity (50% lethal dose).
Main Results:
- Significant schedule-dependent enhancement of tumor cell killing observed.
- Maximal tumor cell killing occurred when tirapazamine was administered 2-3 hours before cisplatin.
- Tirapazamine did not enhance cisplatin-induced kidney damage or systemic toxicity.
- Combined drug-induced leukopenia was additive.
Conclusions:
- Tirapazamine and cisplatin combination therapy demonstrates a significant therapeutic advantage.
- This combination is a promising approach for treating hypoxic tumors.
- The observed toxicity profile supports further clinical investigation.